Streetbeat News

Stock Prices

MRNA

Moderna's shares are rising following the approval of a Drug Establishment License for its manufacturing facility in Laval, Quebec, by Health Canada.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:03 pm

GOOGL

IYF

PLTR

XOM

The CNBC Halftime Report highlighted final trades including Exxon Mobil, Alphabet Inc. - Class A, Palantir Technologies, and iShares U.S. Financial ETF. These stocks and ETF are recommended for investors to consider.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:02 pm

BTCUSD

A Bernstein report suggests that the 2024 U.S. presidential election could significantly impact Bitcoin's price. A Trump victory might propel Bitcoin to $80,000-$90,000, while a Harris win could see it drop to $30,000-$40,000. The report highlights the crypto industry's warmer reception from the Trump camp and the challenging regulatory environment.

Portfolio Pulse from Khyathi Dalal

September 09, 2024 | 5:01 pm

KR

Kroger (NYSE:KR) has received mixed analyst ratings, with a majority being somewhat bullish. The average 12-month price target is $61.62, with a high of $72.00 and a low of $57.00. Analysts have adjusted their ratings and price targets based on market dynamics and company performance. Kroger's financials show positive revenue growth, strong net margin, and efficient asset management, despite a lower growth rate compared to peers.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:01 pm

HURN

In the past three months, four analysts have evaluated Huron Consulting Group (NASDAQ:HURN), with ratings ranging from bullish to somewhat bullish. The average 12-month price target is $138.5, reflecting a slight increase from previous estimates. Analysts maintain positive ratings, with Barrington Research and Benchmark providing 'Outperform' and 'Buy' ratings, respectively. Huron Consulting's financial health is strong, with impressive net margins and return on equity, despite facing growth challenges compared to industry peers.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:01 pm

BNTX

MRNA

PFE

Moderna's stock rose after its Laval, Quebec facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically. This milestone supports Moderna's strategic partnership with Canada and enhances its global manufacturing footprint.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 5:00 pm

SOFI

Investors with significant capital are showing a bullish stance on SoFi Techs (NASDAQ:SOFI), as evidenced by recent options trading activity. Benzinga's options scanner detected 11 trades, with a majority being call options, indicating a positive sentiment. The predicted price range for SOFI is between $4.0 and $10.0. The stock is currently trading at $7.16, up 2.14%, with RSI indicators suggesting it may be nearing overbought territory.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:00 pm

CLDX

Analysts have mixed ratings for Celldex Therapeutics (NASDAQ:CLDX), with a range of bullish to bearish sentiments. The average 12-month price target is $68.29, slightly up from the previous $68.00. The company has shown significant revenue growth but struggles with profitability and asset returns.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:00 pm

ANF

Abercrombie & Fitch (NYSE:ANF) has outperformed the market over the past 10 years with an average annual return of 12.47%, resulting in a $1000 investment growing to $3,291.26. The article highlights the impact of compounded returns over time.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:00 pm

AME

AMETEK (NYSE:AME) has significantly outperformed the market over the past 15 years, with an annualized return of 17.06%. A $100 investment in AME 15 years ago would now be worth $1,071.46, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 5:00 pm